Skip to main content

Table 5 Absorbed dose delivered by each daughter* for selected tissues

From: Dosimetric impact of Ac-227 in accelerator-produced Ac-225 for alpha-emitter radiopharmaceutical therapy of patients with hematological malignancies: a pharmacokinetic modeling analysis

 

Absorbed Dose (mGy/1 MBq 225/7Ac Administered); RBEnot applied

225Ac

221Fr

217At

213Bi

213Po

209Pb

209Tl

227Ac

227Th

223Ra

219Rn

215Po

211Pb

211Bi

207Tl

211Po

Red marrow

1.61E+02

1.71E+02

1.88E+02

1.23E+00

2.09E+01

4.50E−01

3.22E−02

1.87E−04

5.06E−03

3.38E−04

3.99E−04

4.37E−04

3.51E−05

3.86E−04

3.76E−05

1.21E−06

Spleen

1.10E+02

1.20E+02

1.34E+02

7.67E−01

1.13E+01

2.66E−01

2.43E−02

1.10E−04

6.19E−03

1.05E−05

1.20E−05

1.29E−05

1.01E−06

1.16E−05

9.00E−07

3.59E−08

Endosteal bone surface

7.41E+01

7.89E+01

8.61E+01

5.56E−01

9.30E+00

1.85E−01

1.47E−02

7.77E−05

5.63E−03

2.81E−03

3.24E−03

3.34E−03

6.05E−05

3.18E−03

5.84E−05

9.24E−06

Liver

1.53E+01

1.66E+01

1.86E+01

3.88E−01

5.39E+00

1.29E−01

1.51E−02

1.53E−05

6.50E−04

7.86E−06

8.91E−06

9.53E−06

8.64E−07

8.61E−06

7.46E−07

2.66E−08

Lungs

1.13E+00

1.24E+00

1.36E+00

7.45E−02

7.88E−01

2.03E−02

5.32E−03

8.35E−07

6.10E−05

1.92E−05

2.22E−05

2.40E−05

2.17E−06

2.15E−05

2.13E−06

6.67E−08

Kidneys

4.64E−01

5.14E−01

5.48E−01

1.44E−02

3.34E−06

3.59E−04

3.92E−03

3.37E−07

5.64E−04

8.11E−06

9.09E−06

9.67E−06

8.81E−07

8.78E−06

6.97E−07

2.70E−08

Pancreas

3.46E−01

3.85E−01

4.06E−01

2.89E−02

2.35E−01

5.69E−03

4.32E−03

2.46E−07

2.13E−05

6.13E−06

6.78E−06

7.16E−06

6.83E−07

6.54E−06

4.89E−07

2.00E−08

Adrenals

3.33E−01

3.80E−01

3.80E−01

4.63E−02

2.20E−01

6.86E−03

7.50E−03

2.56E−07

2.33E−05

6.04E−06

6.47E−06

6.70E−06

1.11E−06

6.23E−06

8.51E−07

1.87E−08

Heart wall

2.89E−01

3.22E−01

3.36E−01

2.77E−02

1.95E−01

5.19E−03

3.96E−03

2.18E−07

1.78E−05

5.08E−06

5.62E−06

5.93E−06

6.41E−07

5.42E−06

4.92E−07

1.66E−08

Thyroid

2.57E−01

2.87E−01

3.02E−01

1.88E−02

1.75E−01

4.06E−03

2.68E−03

1.83E−07

1.56E−05

4.81E−06

5.14E−06

5.32E−06

6.59E−07

4.95E−06

4.07E−07

1.49E−08

Ovaries

1.45E−01

1.66E−01

1.66E−01

1.37E−02

9.59E−02

2.25E−03

2.46E−03

1.03E−07

2.35E−04

3.00E−06

2.96E−06

2.92E−06

6.22E−07

2.82E−06

3.77E−07

8.21E−09

Thymus

1.04E−01

1.22E−01

1.10E−01

2.49E−02

6.35E−02

2.97E−03

4.09E−03

1.12E−07

8.70E−06

2.21E−06

2.06E−06

1.93E−06

1.15E−06

1.95E−06

9.85E−07

5.48E−09

Uterus

9.85E−02

1.15E−01

1.10E−01

1.14E−02

6.35E−02

1.53E−03

2.28E−03

7.00E−08

9.24E−06

2.16E−06

2.03E−06

1.93E−06

5.15E−07

1.93E−06

2.77E−07

5.47E−09

Breast

9.43E−02

1.07E−01

1.10E−01

9.37E−03

6.35E−02

1.51E−03

1.79E−03

6.85E−08

6.10E−06

1.72E−06

1.87E−06

1.93E−06

2.56E−07

1.79E−06

1.62E−07

5.41E−09

Brain

7.58E−02

8.61E−02

8.71E−02

9.24E−03

5.05E−02

1.51E−03

1.41E−03

5.68E−08

5.96E−06

2.29E−06

1.86E−06

1.54E−06

1.76E−06

1.73E−06

1.51E−06

4.43E−09

Muscle

5.22E−02

6.08E−02

5.74E−02

9.60E−03

3.32E−02

1.27E−03

1.61E−03

4.26E−08

4.48E−06

1.33E−06

1.15E−06

1.01E−06

9.87E−07

1.08E−06

8.74E−07

2.89E−09

Salivary glands

5.12E−03

1.06E−02

8.96E−05

5.67E−03

1.36E−06

1.13E−04

1.61E−03

4.54E−09

2.44E−06

9.21E−07

3.92E−07

1.19E−09

1.34E−06

3.21E−07

1.09E−06

1.47E−10

Eye lens

2.34E−03

5.22E−03

4.54E−05

2.56E−03

7.45E−07

1.02E−06

8.29E−04

1.63E−09

1.45E−06

6.46E−07

2.88E−07

9.11E−10

3.42E−07

2.34E−07

4.39E−08

1.08E−10

  1. *Contributions from the 1% decay of 227Ac to 223Fr and daughters with a yield of less than 10–4% are not included